Ganaxolone - Generic Drug Details

✉ Email this page to a colleague

What are the generic sources for ganaxolone and what is the scope of freedom to operate?

Ganaxolone is the generic ingredient in one branded drug marketed by Marinus and is included in one NDA. There are eight patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Ganaxolone has forty-three patent family members in fifteen countries.

One supplier is listed for this compound.

Summary for ganaxolone

International Patents:	43
US Patents:	8
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	46
Clinical Trials:	24
Patent Applications:	937
What excipients (inactive ingredients) are in ganaxolone?	ganaxolone excipients list
DailyMed Link:	ganaxolone at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for ganaxolone

Generic Entry Date for ganaxolone^: ⤷ Subscribe* Constraining patent/regulatory exclusivity: TREATMENT OF SEIZURES ASSOCIATED WITH CYCLIN-DEPENDENT KINASE-LIKE 5 (CDKL5) DEFICIENCY DISORDER (CDD) IN PATIENTS 2 YEARS OF AGE AND OLDER Dosage: SUSPENSION;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for ganaxolone

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Massachusetts General Hospital	N/A
Marinus Pharmaceuticals	Phase 3
Jed E. Rose	Phase 2

See all ganaxolone clinical trials

Pharmacology for ganaxolone

Drug Class	Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator
Mechanism of Action	GABA A Receptor Positive Modulators

Anatomical Therapeutic Chemical (ATC) Classes for ganaxolone

N03AX	Other antiepileptics
N03A	ANTIEPILEPTICS
N03	ANTIEPILEPTICS
N	Nervous system

US Patents and Regulatory Information for ganaxolone

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Marinus	ZTALMY	ganaxolone	SUSPENSION;ORAL	215904-001	Jun 1, 2022		RX	Yes	Yes	8,318,714	⤷ Subscribe	Y			⤷ Subscribe
Marinus	ZTALMY	ganaxolone	SUSPENSION;ORAL	215904-001	Jun 1, 2022		RX	Yes	Yes	⤷ Subscribe	⤷ Subscribe				⤷ Subscribe
Marinus	ZTALMY	ganaxolone	SUSPENSION;ORAL	215904-001	Jun 1, 2022		RX	Yes	Yes	9,029,355	⤷ Subscribe	Y			⤷ Subscribe
Marinus	ZTALMY	ganaxolone	SUSPENSION;ORAL	215904-001	Jun 1, 2022		RX	Yes	Yes	8,367,651	⤷ Subscribe	Y			⤷ Subscribe
Marinus	ZTALMY	ganaxolone	SUSPENSION;ORAL	215904-001	Jun 1, 2022		RX	Yes	Yes	⤷ Subscribe	⤷ Subscribe				⤷ Subscribe
Marinus	ZTALMY	ganaxolone	SUSPENSION;ORAL	215904-001	Jun 1, 2022		RX	Yes	Yes	8,022,054	⤷ Subscribe	Y			⤷ Subscribe
Marinus	ZTALMY	ganaxolone	SUSPENSION;ORAL	215904-001	Jun 1, 2022		RX	Yes	Yes	10,603,308	⤷ Subscribe				⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

EU/EMA Drug Approvals for ganaxolone

Subscribe to access the full database, or Subscribe
Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Marinus Pharmaceuticals Emerald Limited	Ztalmy	ganaxolone	EMEA/H/C/005825 Ztalmy is indicated for the adjunctive treatment of epileptic seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients 2 to 17 years of age. Ztalmy may be continued in patients 18 years of age and older.	Authorised	no	no	yes	2023-07-26
>Company	>Drugname	>Inn	>Product Number / Indication	>Status	>Generic	>Biosimilar	>Orphan	>Marketing Authorisation	>Marketing Refusal

International Patents for ganaxolone

Subscribe to access the full database, or Subscribe
Country	Patent Number	Title	Estimated Expiration
European Patent Office	3481387	METHODES ET COMPOSITIONS POUR LE TRAITEMENT DE TROUBLES ÉPILEPTIQUES (METHODS AND COMPOSITIONS FOR TREATMENT OF EPILEPTIC DISORDERS)	⤷ Subscribe
Colombia	2019001193	Métodos y composiciones para el tratamiento de trastornos epilépticos	⤷ Subscribe
China	109715151	用于治疗癫痫性紊乱的方法和组合物 (METHODS AND COMPOSITIONS FOR TREATMENT OF EPILEPTIC DISORDERS)	⤷ Subscribe
Spain	2812250		⤷ Subscribe
European Patent Office	3586845	COMPOSITIONS POUR LE TRAITEMENT DU TREMBLEMENT ESSENTIEL (COMPOSITIONS FOR TREATMENT OF ESSENTIAL TREMOR)	⤷ Subscribe
Canada	3032686	METHODES ET COMPOSITIONS POUR LE TRAITEMENT DE TROUBLES EPILEPTIQUES (USE OF GANAXOLONE FOR TREATING STATUS EPILEPTICUS IN A SUBJECT)	⤷ Subscribe
China	106667918	加奈索酮组合物及其制备和使用方法 (GANAXOLONE FORMULATIONS AND METHODS FOR THE MAKING AND USE THEREOF)	⤷ Subscribe
>Country	>Patent Number	>Title	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.